ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

October 02, 2007 10:20 ET

ALDA Pharmaceuticals Retains U.S. Legal Counsel

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 2, 2007) - ALDA Pharmaceuticals Corp. (the "Company" or "ALDA") (TSX VENTURE:APH) announces that Stanislaw Ashbaugh, LLP, located in Seattle, Washington, has been retained to assist the Company with U.S. securities law matters. Dr. Terrance Owen, President and CEO states, "In March 2006, the Company completed the filing of its initial 20-F registration statement but we let the matter rest until recently while we contemplated our foreign registration strategies."

About Stanislaw Ashbaugh

Stanislaw Ashbaugh, LLP, acts as general corporate counsel to private and public companies engaged in a wide variety of business activities, including middle-sized and emerging growth companies. Of particular interest to ALDA, the broad range of counsel provided by the Corporate/Securities Law Group includes compliance and reporting under federal and state securities laws and secondary financings.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The statements contained in this news release that are not purely historical are forward-looking statements. "Forward looking statements" include statements regarding our expectations, hopes, intentions or strategies regarding the future. Forward looking statements include: statements regarding future products or products or product development; statements regarding future selling, general and administrative costs and research and development spending; and our product development strategy; statements regarding future capital expenditures and financing requirements; and similar forward looking statements. It is important to note that our actual results could differ materially from those in such forward-looking statements. The Company disclaims any obligation to revise any forward looking statements as a result of information received after the fact or regarding future events.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information